Shares of Insmed Incorporated (NASDAQ:INSM – Get Free Report) have been given a consensus rating of “Buy” by the sixteen ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

Praxis on Friday said the independent data monitoring committee overseeing an interim analysis of Study 1 of the "Essential3" program has recommended that the study be stopped for futility because it ...